Strong collaborations and test beds are important when it comes to the change in life science. Toleranzia received funding from Swelife for their collaboration with Testa Center and presented new and positive results.
TEXT: ANNIKA ÅKERVALL
The pharmaceutical company in Biotech Center @Sahlgrenska SP has developed a platform technology for the treatment of autoimmune diseases. The technology enables the production of drugs that target the cause of the disease – not just the symptoms, which is currently the common treatment. The main project is aimed at an autoimmune nerve muscle disease, myasthenia gravis, for which there is a great need for improved medical treatment.
“We are very happy to have been selected to receive funding from Swelife, which is an important recognition for the TOL2 project,” says Charlotte Fribert, CEO of Toleranzia, in a press release.
Through this financing, the company will be able to validate the process on a larger scale and produce materials for the development of the formulation of TOL 2 for clinical studies.
Recently, positive, preliminary results were also presented from a toxicological study with TOL2, which was carried out in collaboration with RISE, which Nyhetsbyrån Direkt reported on.
Photo of Charlotte Fribert, CEO, Toleranzia. She is one of the members of our CEO network @Sahlgrenska SP.
LEARN MORE: VD-klubben @Sahlgrenska SP
Sahlgrenska Science Park is the West Swedish coordinator for Swelife and new calls will be presented on our site.
Facts: Toleranzia is listed on Aktietorget since 2015. The Gothenburg company was started via GU Ventures in 2012 and has offices in the Biotech Center @Sahlgrenska SP. The Swedish Government’s ambition is to make Sweden a global leader in the production, research and development of biopharmaceutical products. As part of this, they have established Testa Center through Vinnova and GE Healthcare, with the intention of creating a new, state-of-the-art center for verifying innovative projects.